<?xml version="1.0" encoding="UTF-8"?>
<p>In China, Chinese medicine (CM) is proposed as a treatment option by national and provincial guidelines with substantial utilization.
 <sup>[
  <xref rid="R18" ref-type="bibr">18</xref>]
 </sup> During the outbreak of SARS, CM was introduced as a treatment option since the early situation of epidemic in China. There are 3 clinical trials have proved the effectiveness of CM in the treatment of SARS.
 <sup>[
  <xref rid="R19" ref-type="bibr">19</xref>]
 </sup> The sixth version of China national clinical guideline on COVID-19 associated pneumonia was published on February 18, 2020, the national guideline divided COVID-19 into medical observation period and treatment period. The recommended formulation during medical observation period involved huo-xiang-zheng-qi capsule and jin-hua-qing-gan granules, lian-hua-qing-wen capsule or shu-feng-jie-du capsule. The treatment period is divided into 4
</p>
